Literature DB >> 18573107

The role of NF-kappaB in lymphoid malignancies.

Graham Packham1.   

Abstract

Nuclear Factor kappaB (NF-kappaB) transcription factors are central regulators of lymphocyte proliferation, survival and development. Although normally subject to tight control, constitutive activation of NF-kappaB promotes inappropriate lymphocyte survival and proliferation, and is recognised as key pathological feature in various lymphoid malignancies. Inhibition of NF-kappaB may be an attractive therapeutic approach in these diseases. This review focuses on the mechanisms and functional consequences of NF-kappaB activation in lymphoid malignancies and potential therapeutic strategies for inhibition of NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18573107     DOI: 10.1111/j.1365-2141.2008.07284.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  25 in total

1.  Activation of IKK/NF-κB provokes renal inflammatory responses in guanylyl cyclase/natriuretic peptide receptor-A gene-knockout mice.

Authors:  Subhankar Das; Ramu Periyasamy; Kailash N Pandey
Journal:  Physiol Genomics       Date:  2012-02-07       Impact factor: 3.107

Review 2.  Phosphorylation/de-phosphorylation in specific sites of tumor suppressor WWOX and control of distinct biological events.

Authors:  Shenq-Shyang Huang; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-08

3.  Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

Authors:  Ashish Juvekar; Subrata Manna; Sitharam Ramaswami; Tzu-Pei Chang; Hai-Yen Vu; Chandra C Ghosh; Mahmut Y Celiker; Ivana Vancurova
Journal:  Mol Cancer Res       Date:  2011-01-11       Impact factor: 5.852

Review 4.  Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development.

Authors:  Xavier Sagaert; Eric Van Cutsem; Gert De Hertogh; Karel Geboes; Thomas Tousseyn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-04       Impact factor: 46.802

Review 5.  A20: from ubiquitin editing to tumour suppression.

Authors:  Sarah G Hymowitz; Ingrid E Wertz
Journal:  Nat Rev Cancer       Date:  2010-04-12       Impact factor: 60.716

6.  Activation of noncanonical NF-kappaB signaling by the oncoprotein Tio.

Authors:  Sarah Jill de Jong; Jens-Christian Albrecht; Monika Schmidt; Ingrid Müller-Fleckenstein; Brigitte Biesinger
Journal:  J Biol Chem       Date:  2010-03-30       Impact factor: 5.157

7.  Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice.

Authors:  Anwaar Ahmad; Jason S Groshong; Hittu Matta; Sandra Schamus; Vasu Punj; Lisa J Robinson; Parkash S Gill; Preet M Chaudhary
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

Review 8.  New targets for the antitumor activity of gambogic acid in hematologic malignancies.

Authors:  Li-jing Yang; Yan Chen
Journal:  Acta Pharmacol Sin       Date:  2012-12-31       Impact factor: 6.150

9.  Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.

Authors:  Hyun Joo Jung; Zheng Chen; Nami McCarty
Journal:  Am J Hematol       Date:  2012-09-11       Impact factor: 10.047

10.  Identification of a novel motif responsible for the distinctive transforming activity of human T-cell leukemia virus (HTLV) type 1 Tax1 protein from HTLV-2 Tax2.

Authors:  Toshiyuki Shoji; Masaya Higuchi; Rie Kondo; Masahiko Takahashi; Masayasu Oie; Yuetsu Tanaka; Yutaka Aoyagi; Masahiro Fujii
Journal:  Retrovirology       Date:  2009-09-17       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.